CYP11B2 and cardiovascular disorder: Previous studies have shown that 5–10 mmHg reductions in SBP are associated with reduced risk of cardiovascular disease and death.19,20 The BP lowering effects of baxdrostat in our study were consistent with those reported for the aldosterone synthase inhibitor lorundrostat.21,22 In a phase 3 trial in patients with uncontrolled and resistant hypertension, the placebo-adjusted reduction in office SBP with lorundrostat 50 mg was –9.1 mmHg (95% CI, –13.3 to –4.9) at week 6 (primary endpoint).21